Skip to contentT
Travere Therapeutics, Inc.
T
TVTXTravere Therapeutics, Inc. Q4 2019 · 10-K
Revenue$46.69M$46.69M+6.7% vs Q4 2018 Net Income-$30.26M-$30.26MN/M vs Q4 2018 EPS Diluted-$0.70-$0.70N/M vs Q4 2018 Operating Income-$28,167,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Travere Therapeutics, Inc. · CIK 1438533 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$4,401,000N/M Margins · derivedOperating margin-60.3%−48.9 pt vs Q4 2018
Net margin-64.8%−47.8 pt vs Q4 2018
ended Dec 31, 2019 · filed Feb 24, 2020 · 55 d after period end